Sugi Predict

Sugi Predict / Compounds / SCHEMBL1758264

SCHEMBL1758264

SCHEMBL1758264

O=C1C(=O)c2ccc(Cl)cc2-c2ccccc21

nearest known ligand 0.91

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S100A4 P26447 5/20 0.91
▸ PTPRC P08575 9/20 0.59
▸ MEN1 O00255 4/20 0.59
▸ KMT2A Q03164 4/20 0.59
▸ APAF1 O14727 3/20 0.59
▸ NPC1 O15118 3/20 0.59
▸ LMNA P02545 3/20 0.59
▸ HTT P42858 3/20 0.59
▸ RAB9A P51151 3/20 0.59
▸ GALK1 P51570 3/20 0.59
▸ BLM P54132 3/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ NPSR1 Q6W5P4 3/20 0.59
▸ MAPT P10636 2/20 0.59
▸ THRB P10828 2/20 0.59
▸ TDP2 O95551 2/20 0.59
▸ PLA2G1B P04054 2/20 0.59
▸ POLB P06746 2/20 0.59
▸ PLCG1 P19174 2/20 0.59
▸ PPARG P37231 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2599398 0.95 S100A4 (1.00) S100A4PTPRCMEN1KMT2AAPAF1
SCHEMBL8675120 0.95 S100A4 (0.83) S100A4PTPRCMEN1KMT2AAPAF1
SCHEMBL30419890 0.91 S100A4 (0.91) S100A4PTPRCMEN1KMT2AAPAF1
SCHEMBL301388 0.91 S100A4 (0.91) S100A4PTPRCMEN1KMT2AAPAF1
SCHEMBL38651099 0.91 S100A4 (0.91) S100A4PTPRCMEN1KMT2AAPAF1
SCHEMBL11876117 0.91 S100A4 (0.80) S100A4PTPRCMEN1KMT2AAPAF1
SCHEMBL155593 0.88 S100A4 (0.87) S100A4PTPRCMEN1KMT2AAPAF1
Anthraquinone SCHEMBL10531854 0.88 S100A4 (0.87) S100A4PTPRCMEN1KMT2AAPAF1
SCHEMBL29378883 0.88 S100A4 (0.87) S100A4PTPRCMEN1KMT2AAPAF1
SCHEMBL7799443 0.88 S100A4 (0.70) S100A4PTPRCLMNAPTPN1ITGA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828143-B1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD (CA) 2013-03-20 — — EP disclosed
US-7943649-B2 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors MERCK FROSST CANADA LTD. (CA) 2011-05-17 — — US disclosed
US-20090286772-A1 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles MERCK & CO., INC. 2009-11-19 — — US disclosed
EP-1828143-A4 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD (CA) 2009-08-26 — — EP disclosed
US-20090192158-A1 Methods for Treating or Preventing Neoplasias MERCK FROSST CANADA LTD. (CA) 2009-07-30 — — US disclosed
EP-1989187-A4 2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO (9,10-D) IMIDAZOLES MERCK FROSST CANADA LTD (CA) 2009-07-08 — — EP disclosed
US-20090075998-A1 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors MERCK CANADA INC. (CA) 2009-03-19 — — US disclosed
EP-2019675-A1 METHODS FOR TREATING OR PREVENTING NEOPLASIAS Merck Frosst Canada Ltd. (CA) 2009-02-04 — — EP disclosed
EP-1989187-A1 2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO (9,10-D) IMIDAZOLES Merck Frosst Canada Ltd. (CA) 2008-11-12 — — EP disclosed
US-7442716-B2 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors MERCK FROSST CANADA LTD. (CA) 2008-10-28 — — US disclosed
EP-1954683-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO(9,10-D)IMIDAZOLES AS MPGES-1 INHIBITORS Merck Frosst Canada Ltd. (CA) 2008-08-13 — — EP disclosed
WO-2007124589-A1 METHODS FOR TREATING OR PREVENTING NEOPLASIAS MERCK FROSST CANADA LTD. (CA) 2007-11-08 — — WO disclosed
US-20070208017-A1 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors MERCK CANADA INC. (CA) 2007-09-06 — — US disclosed
EP-1828143-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS Merck Frosst Canada Ltd. (CA) 2007-09-05 — — EP disclosed
WO-2007095753-A1 2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO [9,10-D] IMIDAZOLES MERCK FROSST CANADA LTD. (CA) 2007-08-30 — — WO disclosed
WO-2007059610-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-05-31 — — WO disclosed
WO-2007059611-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-05-31 — — WO disclosed
WO-2006063466-A1 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS MERCK FROSST CANADA LTD. (CA) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286772-A1 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles PTGES, PTGS1, PTGES2 S100A4 2484/4885PTPRC 2890/4885MEN1 4018/4885
US-20090192158-A1 Methods for Treating or Preventing Neoplasias GSTO1, PTGS1, PTGES S100A4 1713/4885PTPRC 2752/4885MEN1 929/4885
US-20070208017-A1 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors PTGS1, PTGES, PTGES2 S100A4 3955/4885PTPRC 2130/4885MEN1 4188/4885
US-20090075998-A1 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors PTGS1, PTGES, PTGES2 S100A4 3955/4885PTPRC 2130/4885MEN1 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.